You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
A股午間公吿:艾德生物產品在日本獲批 金沃股份籌劃股權激勵計劃

1.艾德生物:公司自主研發的FGFR2基因斷裂檢測試劑盒(熒光原位雜交法)近日獲得日本厚生勞動省批准上市。該產品預期用途為檢測腫瘤組織中FGFR2基因融合或重排(用於幫助確定膽管癌患者是否適合服用Tasurgratinib)。該產品的獲批,進一步豐富了公司腫瘤伴隨診斷產品線。2.金沃股份:公司籌劃實施限制性股票激勵計劃,擬授予激勵對象權益總計不超過330萬股,佔公司目前股本總額7680.19萬股的4.3%。股票來源為公司向激勵對象定向發行的股票以及公司回購的股份。3.大宏立:鑑於成都大宏立建築材料有限公司(簡稱“合資公司”)成立至今,未實際開展業務,且公司未實際出資,為優化產業結構,公司決定退出合資公司。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account